Related Experiment Video
Updated: Aug 15, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
Anti-tumor surveillance of non-contact-inhibited transformed cell lines
1Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO 63110.
Abstract:
In order to determine if the correlated expression of transformation and tumorigenicity is affected by the agents used to induce transformants or by the immune status of the host used to test the tumorigenicity of transformants, we derived a series of cloned cell lines from foci of transformed cells induced by treatment of the contact-inhibited mouse cell line B/C-N7.ICI with the DNA demethylating agent 5-azacytidine (5-AZC) or the DNA demethylating and mutating agent benzo(a)pyrene dihydrodiol epoxide (BPDE). The transformed cell lines were injected into syngeneic nude and normal mice to determine their tumorigenicity. The results of this analysis showed that 93% of the transformants induced by 5-AZC treatment grew as tumors when injected into nude mice. Of those lines capable of growing as tumors in nude mice, 86% were also tumorigenic when injected into normal mice. In contrast, only 64% of BPDE-induced transformants grew as tumors in nude mice, and of those, only 44% were also tumorigenic in normal mice. The existence of non-contact-inhibited transformants that are tumorigenic only in nude mice indicates that host anti-tumor immune surveillance mechanisms are operative in normal mice. Further, the difference in both the percentage of transformed cell lines that are tumorigenic and the percentage of tumorigenic transformants that are susceptible to immune surveillance when transformants are induced by BPDE as compared to 5-AZC indicates that the transforming agent can affect both the correlation between the expression of transformation and tumorigenicity, and the interaction between the immune system and tumorigenic transformants.
Insights
The transforming agent influences cancer development and immune response. DNA demethylating agents like 5-azacytidine (5-AZC) lead to higher tumor formation and immune evasion compared to mutagenic agents like benzo(a)pyrene dihydrodiol epoxide (BPDE).
Area of Science:
- Cell biology
- Cancer research
- Immunology
Background:
- Transformation and tumorigenicity are key aspects of cancer development.
- The influence of inducing agents and host immune status on these processes is not fully understood.
Purpose of the Study:
- To investigate how DNA demethylating agents (5-azacytidine) versus mutagenic agents (benzo(a)pyrene dihydrodiol epoxide) affect the correlation between cell transformation and tumorigenicity.
- To determine the role of host immune status in the tumorigenicity of induced transformants.
Main Methods:
- Derived cloned cell lines from transformed mouse cells induced by 5-azacytidine or BPDE.
- Injected these transformed cell lines into syngeneic nude (immunocompromised) and normal (immune-competent) mice to assess tumorigenicity.
Main Results:
- 5-azacytidine induced transformants showed higher tumorigenicity in nude mice (93%) and normal mice (86% of those tumorigenic in nude mice).
- BPDE-induced transformants had lower tumorigenicity in nude mice (64%) and significantly lower in normal mice (44% of those tumorigenic in nude mice).
- The data suggest that host anti-tumor immune surveillance is active and that the transforming agent impacts both tumorigenicity and immune susceptibility.
Conclusions:
- The transforming agent significantly affects the correlation between cell transformation and tumorigenicity.
- Host immune status plays a critical role in determining tumor development, with different agents inducing transformants that vary in their susceptibility to immune surveillance.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
05:21Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay
Published on: September 13, 2024